Literature DB >> 6542017

Production of the effector molecule thymidine by human lung alveolar macrophages.

A Vercammen-Grandjean, R Arnould, A Libert, P Ewalenko, F Lejeune.   

Abstract

Cultured human alveolar macrophages (HAM phi) were found to produce soluble factors which inhibit tritiated thymidine [( 3H]-TdR) incorporation into tumour cells in vitro. We present evidence that thymidine (TdR) can be detected in HAM phi culture supernatants by thin-layer chromatography. Moreover, TdR secretion by HAM phi is an active process. Using [6-14C]-orotic acid as an early precursor to TdR and [3H]-TMP as the phosphorylation product, we were able to show that cultured HAM phi transformed them into labelled TdR. The very efficient thin-layer chromatography of the labelled metabolites was backed up by high-pressure liquid chromatography of nucleotides. HAM phi produce TdR by de novo synthesis and dephosphorylation. This phenomenon is due to the lack of thymidine kinase in normal mature macrophages. Since TdR, in high concentrations, can inhibit DNA synthesis through the 'TdR blockade' phenomenon, it is suggested that TdR secretion by HAM phi is a mechanism of non-specific modulation of tumour cell growth but highly restricted to the immediate macrophage microenvironment in vivo. The effectiveness of the thymidine gradient may thus be quite narrow, but is worthy of interest.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6542017     DOI: 10.1016/0277-5379(84)90148-2

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  2 in total

1.  Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'-deoxythymidine (zidovudine) in human mononuclear cells.

Authors:  J Szebeni; S S Patel; K Hung; L M Wahl; J N Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages.

Authors:  D D Richman; R S Kornbluth; D A Carson
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.